Armata to present data on AP-SA02's genetic diversity effectiveness against Staph aureus
Armata Pharmaceuticals will present new data on its AP-SA02 phage therapy at ISSSI 2026 on Sept. 21, 2026. The results suggest that controlled genetic diversity in the phage cocktail can improve the killing of certain Staphylococcus aureus clinical isolates. Manufacturing processes are designed to maintain consistent d